The potential economic benefits of improved postfracture care: A cost-effectiveness analysis of a fracture liaison service in the US health-care system

Journal of Bone and Mineral Research

Volumn 29, Issue 7, 2014, Pages 1667-1674

  Solomon, Daniel H ^a   Patrick, Amanda R ^a   Schousboe, John ^b   Losina, Elena ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HEALTHPARTNERS INSTITUTE   (United States)

Author keywords

COST EFFECTIVENESS; FRACTURE LIAISON SERVICE; HIP FRACTURE; OSTEOPOROSIS

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ZOLEDRONIC ACID;

AGED; ARTICLE; BONE DENSITOMETRY; BONE DISEASE; COMPUTER SIMULATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; FOREARM FRACTURE; FRACTURE; FRACTURE LIAISON SERVICE; GASTROINTESTINAL SYMPTOM; HEALTH CARE; HEALTH CARE SYSTEM; HEALTH SERVICE; HEALTH STATUS; HIP FRACTURE; HUMAN; MALE; OSTEOPOROSIS; POSTFRACTURE CARE; QUALITY ADJUSTED LIFE YEAR; SPINE FRACTURE; UNITED STATES; WRIST FRACTURE; COST BENEFIT ANALYSIS; ECONOMICS; FRACTURES, BONE; HEALTH CARE DELIVERY; MORTALITY; STATISTICAL MODEL; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; MALE; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; UNITED STATES;

EID: 84897542404     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2180     Document Type: Article

References (57)

1. Board of Trustees FHITF. Annual report. 2012; In: Services HaH, editor. p. 60. Report available at: http://www.treasury.gov/resource-center/economic- policy/ss-medicare/Documents/TR-2012-Medicare.pdf
2. National Committee for Quality Assurance. The state of health care quality. Washington, DC: NCQA; 2010; p. 94. 2010.
3. Recker RR, Lewiecki EM, Miller PD, Reiffel J., Safety of bisphosphonates in the treatment of osteoporosis. Am J Med. 2009; 122 (2 Suppl): S22-32.
4. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1): CD001155.
5. Dell R., Fracture prevention in Kaiser Permanente Southern California. Osteoporos Int. 2011; 22 (Suppl 3): 457-60.
6. Newman ED, Ayoub WT, Starkey RH, Diehl JM, Wood GC., Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int. 2003; 14 (2): 146-51.
7. Cadarette SM, Katz JN, Brookhart MA, et al. Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004. J Rheumatol. 2008; 35 (2): 319-26.
8. McLellan AR, Wolowacz SE, Zimovetz EA, et al. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011; 22 (7): 2083-98.
9. Gold MR, Siegel JE, Russel LB, Weinstein M., Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
10. Patrick AR, Schousboe JT, Losina E, Solomon DH., The economics of improving medication adherence in osteoporosis: validation and application of a simulation model. J Clin Endocrinol Metab. 2011; 96 (9): 2762-70.
11. Patrick AR, Brookhart MA, Losina E, et al. The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab. 2010; 95 (7): 3251-9.
12. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A., Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007; 22 (3): 465-75.
13. Center JR, Bliuc D, Nguyen TV, Eisman JA., Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007; 297 (4): 387-94.
14. Pike CT, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET., Prevalence and costs of osteoporotic patients with subsequent non-vertebral fractures in the US. Osteoporos Int. 2011; 22 (10): 2611-21.
15. Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial. Arch Intern Med. 2009; 169 (1): 25-31.
16. Johnell O, Kanis JA, Oden A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int. 2004; 15 (3): 175-9.
17. Melton LJ 3rd, Crowson CS, O'Fallon WM., Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int. 1999; 9 (1): 29-37.
18. Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA. 2007; 298 (6): 629-37.
19. Sawka AM, Papaioannou A, Adachi JD, Gafni A, Hanley DA, Thabane L., Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord. 2005; 6: 39.
20. Melton LJ 3rd, Ilstrup DM, Beckenbaugh RD, Riggs BL., Hip fracture recurrence. A population-based study. Clin Orthop Relat Res. 1982; (167): 131-8.
21. Tosteson AN, Jonsson B, Grima DT, O'Brien BJ, Black DM, Adachi JD., Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int. 2001; 12 (10): 849-57.
22. Strom O, Borgstrom F, Kanis JA, Jonsson B., Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int. 2009; 20 (1): 23-34.
23. Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C., Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone. 2003; 33 (3): 301-7.
24. Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med. 2007; 120 (3): 251-6.
25. Weycker D, Macarios D, Edelsberg J, Oster G., Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 2007; 18 (3): 271-7.
26. Tosteson AN, Gottlieb DJ, Radley DC, Fisher ES, Melton LJ 3rd., Excess mortality following hip fracture: the role of underlying health status. Osteoporos Int. 2007; 18 (11): 1463-72.
27. von Friesendorff M, Besjakov J, Akesson K., Long-term survival and fracture risk after hip fracture: a 22-year follow-up in women. J Bone Miner Res. 2008; 23 (11): 1832-41.
28. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR., Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1999; 159 (11): 1215-20.
29. Empana JP, Dargent-Molina P, Breart G., Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc. 2004; 52 (5): 685-90.
30. Haentjens P, Magaziner J, Colon-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010; 152 (6): 380-90.
31. Katz JN, Losina E, Barrett J, et al. Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States Medicare population [see comment]. J Bone Joint Surg Am. 2001; 83-A (11): 1622-9.
32. Thomson Reuters. Red book. Montvale, NJ: Thomson Reuters; 2010; 2010.
33. Thomson Healthcare (Firm). Red book. Montvale, NJ: Thomson PDR; 2007; p. v. 2007.
34. Gabriel SE, Tosteson AN, Leibson CL, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int. 2002; 13 (4): 323-30.
35. Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ., Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc. 2002; 50 (10): 1644-50.
36. Schousboe JT, Nyman JA, Kane RL, Ensrud KE., Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005; 142 (9): 734-41.
37. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A., High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001; 44 (12): 2737-45.
38. Borgstrom F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int. 2006; 17 (5): 637-50.
39. Kanis JA, Johnell O, Oden A, et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int. 2004; 15 (1): 20-6.
40. Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res. 2000; 15 (7): 1384-92.
41. Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd., Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int. 2001; 12 (12): 1042-9.
42. Adachi JD, Faraawi RY, O'Mahony MF, et al. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study. Clin Ther. 2009; 31 (8): 1747-53.
43. Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N., Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int. 2013; 24 (1): 237-44.
44. Gedmintas L, Solomon DH, Kim SC., Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013; 28 (8): 1729-37.
45. Groeneveld PW, Lieu TA, Fendrick AM, et al. Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia. Am J Gastroenterol. 2001; 96 (2): 338-47.
46. Miksad RA, Lai KC, Dodson TB, et al. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist. 2011; 16 (1): 121-32.
47. Najm M, Solomon D, Woo S, Treister N., Resource utilization in cancer patients with bisphosphonate-associated osteonecrosis of the jaw. Oral Dis. 2014; 20 (1): 94-9.
48. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med. 2007; 357: nihpa 40967.
49. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture [see comment]. N Engl J Med. 2007; 357 (18): 1799-809.
50. Gold MR., Cost-effectiveness in health and medicine. New York: Oxford University Press; p. xxiii. 1996.
51. Ryder KM, Cummings SR, Palermo L, et al. Does a history of non-vertebral fracture identify women without osteoporosis for treatment ? J Gen Intern Med. 2008; 23 (8): 1177-81.
52. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2013.
53. Tosi LL, Gliklich R, Kannan K, Koval KJ., The American Orthopaedic Association's "own the bone" initiative to prevent secondary fractures. J Bone Joint Surg Am. 2008; 90 (1): 163-73.
54. American Orthopaedic Association. Own the bone. Rosemont, IL: American Orthopaedic Association; 2013.
55. Chandran M, Tan MZ, Cheen M, Tan SB, Leong M, Lau TC., Secondary prevention of osteoporotic fractures-an "OPTIMAL" model of care from Singapore. Osteoporos Int. 2013; 24 (11): 2809-17.
56. Eisman JA, Bogoch ER, Dell R, et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res. 2012; 27 (10): 2039-46.
57. Arias E., United States life tables, 2004. Natl Vital Stat Rep. 2007; 56 (9): 1-39.